Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
Diane M. Harper(Dartmouth College), Eduardo L. Franco(McGill University), Cosette M. Wheeler(University of New Mexico), Anna‐Barbara Moscicki(Universidade Nove de Julho), Barbara Romanowski(University of Alberta), Cecília Roteli-Martins(Hospital São Paulo), David Jenkins(GlaxoSmithKline (United Kingdom)), Anne Schuind(GlaxoSmithKline (United States)), Sue Ann Costa Clemens(GlaxoSmithKline (Brazil)), Gary Dubin(GlaxoSmithKline (United States))
Cited by 1,636Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis